Kalbe Farma Tbk PT
IDX:KLBF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kalbe Farma Tbk PT
Cash from Operating Activities
Kalbe Farma Tbk PT
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Cash from Operating Activities
Rp3.3T
|
CAGR 3-Years
37%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Cash from Operating Activities
Rp1.5T
|
CAGR 3-Years
45%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Cash from Operating Activities
Rp201.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
14%
|
CAGR 10-Years
-1%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Cash from Operating Activities
Rp896.4B
|
CAGR 3-Years
34%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Cash from Operating Activities
-Rp364.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Cash from Operating Activities
Rp234.4B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
3%
|
|
Kalbe Farma Tbk PT
Glance View
Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.
See Also
What is Kalbe Farma Tbk PT's Cash from Operating Activities?
Cash from Operating Activities
3.3T
IDR
Based on the financial report for Dec 31, 2025, Kalbe Farma Tbk PT's Cash from Operating Activities amounts to 3.3T IDR.
What is Kalbe Farma Tbk PT's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
3%
Over the last year, the Cash from Operating Activities growth was -32%. The average annual Cash from Operating Activities growth rates for Kalbe Farma Tbk PT have been 37% over the past three years , -5% over the past five years , and 3% over the past ten years .